This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



lenalidomide (Revlimid®)


Reference No. 4171

Publication date:
18/09/2019


Appraisal information

lenalidomide (Revlimid®) 2.5 mg capsule
lenalidomide (Revlimid®) 5 mg capsule
lenalidomide (Revlimid®) 7.5 mg capsule
lenalidomide (Revlimid®) 10 mg capsule
lenalidomide (Revlimid®) 15 mg capsule
lenalidomide (Revlimid®) 20 mg capsule
lenalidomide (Revlimid®) 25 mg capsule


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 16/09/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, lenalidomide (Revlimid®) cannot be endorsed for use within NHS Wales as combination therapy with bortezomib and dexamethasone, or melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Statement of Advice (SOA)
Download